Oliva et al. concluded from the MEDALIST trial, in which luspatercept was administered to ESA-resistant patients with MDS and sideroblastic anemia, that improved QoL could be related not to a direct Hb rise but, to decreased transfusion needs [16]. Here, GSTM1 is linked to myelodysplastic syndrome.